Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia

NCT01521494 is registered in ClinicalTrials.gov with Kissei Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT01521494
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01521494 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PA21 Phase II Clinical Study in Hemodialysis Patients With Hyperphosphatemia
Lead sponsor
Kissei Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
January 11, 2012
Completion date
July 3, 2012
Enrollment
183 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease requiring hemodialysis